Benign Prostatic Hyperplasia Treatment Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Cardinal Health Inc.
- NxThera, Inc.
- Veru, Inc.
- Teleflex Incorporated
- Eli Lily & Company
- Sanofi S.A.
- GSK plc
- Mylan N.V.
- AbbVie Inc.
Key strategies adopted by the benign prostatic hyperplasia prostrate treatment market include product launches, strategic partnerships and acquisitions, and geographical expansions. Additionally, players are focusing on regulatory approvals, patient awareness campaigns, and affordable pricing strategies to enhance market penetration and gain a competitive edge. Some of these companies are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of benign prostatic hyperplasia treatment is evaluated at USD 13.73 billion.
The global benign prostatic hyperplasia treatment market size exceeded USD 13.09 billion in 2025 and is set to expand at a CAGR of over 5.4%, surpassing USD 22.15 billion revenue by 2035.
North America in the benign prostatic hyperplasia prostate treatment market is projected to hold the largest share by 2035, owing to rising prevalence, unhealthy lifestyles, and advanced healthcare infrastructure.
Key players in the market include Fillauer LLC, ComfortFit Orthotic Labs, Inc, Hanger, Inc., Amfit Inc., Ascent Meditech Limited., Performance Health Holdings, Inc., DeRoyal Industries, Inc., DJO, LLC, Zimmer Biomet Holdings, Inc., Stryker Corporation, BREG, Inc.
